US 11,655,297 B2
ILDR2 antagonists and combinations thereof
Lars Röse, Berlin (DE); Uwe Gritzan, Cologne (DE); Julia Hütter, Berlin (DE); Spencer Liang, San Mateo, CA (US); Andrew Pow, Burlington, MA (US); John Hunter, Piedmont, CA (US); Ofer Levy, Doar Na Shimson (IL); and Ilan Vaknin, Modiin-Mac-cabim-Reut (IL)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE); Bayer Pharma Aktiengesellschaft, Berlin (DE); and Compugen LTD., Holon (IL)
Appl. No. 16/766,224
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); Bayer Pharma Aktiengesellschaft, Berlin (DE); and Compugen LTD., Holon (IL)
PCT Filed Nov. 28, 2018, PCT No. PCT/EP2018/082779
§ 371(c)(1), (2) Date May 21, 2020,
PCT Pub. No. WO2019/105972, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/592,913, filed on Nov. 30, 2017.
Prior Publication US 2020/0369769 A1, Nov. 26, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/713 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 31/337 (2013.01); A61K 31/713 (2013.01); A61P 35/00 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A pharmaceutical combination comprising an ILDR2 antagonist plus optionally one or more other therapeutically active compounds,
wherein the ILDR2 antagonist is an anti-ILDR2 antibody, or a fragment or derivative thereof, or a modified antibody format, having ILDR2 binding properties which comprises at least the following CDR heavy chain (HC) sequences and paired CDR light chain (LC) sequences:
SEQ ID NO:1 CDR1 HC,
SEQ ID NO:2 CDR2 HC,
SEQ ID NO:3 CDR3 HC,
SEQ ID NO:4 CDR1 LC,
SEQ ID NO:5 CDR2 LC, and
SEQ ID NO:6 CDR3 LC.